Schizophrenia is a debilitating mental illness that affects approximately 1% of the world's population. Despite much research in its neurobiology to aid in developing new treatments, little progress has been made. One system that has not received adequate attention is the kappa opioid system and its potential role in the emergence of symptoms, as well as its therapeutic potential. Here we present an overview of the kappa system, and review various lines of evidence derived from clinical studies for dynorphin/KOR involvement in the pathology of both the positive and negative symptoms of schizophrenia. This will include the evidence for the psychotomimetic effects of kappa opioid agonists in healthy volunteers and their reversal by the pan-opioid antagonists naloxone and naltrexone, as well as the evidence for a therapeutic benefit in schizophrenia for four pan-opioid antagonists. We then describe the interactions between KORs and the dopaminergic pathways that are disrupted in schizophrenia and the histologic evidence suggesting abnormal KOR signaling in schizophrenia. We conclude by discussing future directions.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
4 interacting and communicating with "entities or beings" and five volunteers experienced visual and auditory hallucinations [26] . Finally, in a double-blind study of 24 healthy volunteers, Maqueda et al., 2016 found that, salvinorin A produced both visual and auditory changes that could be blocked by the kappa, mu, and delta antagonist naltrexone ( Table 2) [27].
II. Kappa opioid antagonists have acute antipsychotic effects in patients with schizophrenia
There have been at least thirty two trials investigating the therapeutic potential of four different pan-opioid receptor antagonists in patients with schizophrenia. We present a narrative review of 21 trials of naloxone, eight trials of naltrexone, one trial of nalmefene, and two trials of buprenorphine. Naloxone, naltrexone, and nalmefene, are all antagonists at the kappa, mu, and delta receptor, and buprenorphine is a dual kappa antagonist and mu partial agonist ( Table 3) . While many of these studies have shown impressive and rapid efficacy in the treatment of both positive and negative symptoms, some of these studies have shown mixed results, ranging from non-significant trends toward improvement to complete lack of efficacy. Here we postulate that the mixed results may have been due to differences in trial design including the dose and method of administration of the antagonist, as well as the time-point at which the patient was assessed for effects of the drug. We propose that the success of these trials depended on each of these drugs' ability to antagonize the KOR at physiologically relevant concentrations. Additionally, inclusion of patients with different core symptoms may introduce more heterogeneity. As schizophrenia is a heterogeneous disorder, it is possible that dynorphin and KOR dysregulation might represent a subset of patients with schizophrenia and as such, KOR antagonists may be less effective in patients without KOR dysregulation.
IIa. Naloxone trials
Naloxone is an extremely short acting pan opioid antagonist with a half-life of only 1 hour. In total, nearly all of these studies were designed to test for immediate effects on the positive symptoms of schizophrenia. Here we group them into three categories by dose: 1) 0.4-1.6mg, 2) 4-10mg, and 3) 20mg-2mg/kg. Some of these categories can be further subdivided by method of administration. While some patients responded to the low dose range of 0.4-1.6mg naloxone, most successful naloxone studies used at least 4mg of naloxone delivered intravenously.
In the first group of very low dose naloxone, there were 7 trials and 2 case reports [28, 29] in non-catatonic patients with schizophrenia that administered the dose of 0.4-1.6mg of intravenous (IV) naloxone with improvement on the Brief Psychiatric Rating Scale (BPRS) as an endpoint. Two trials found significant improvement [30, 31] , while the others reported mixed results [32-36].
Successful follow-up studies of naloxone in patients with schizophrenia later recognized that 0.4mg-1.6mg is too low to occupy the majority of opioid receptors in the brain or to see an effect in most patients with schizophrenia [37] . For reference, recent Positron Emission Tomography (PET) imaging has recently shown that a 1mg bolus of IV naloxone in an 80kg person leads to a maximum of 50% opioid receptor occupancy (Table 4) [38]. Each of the negative studies also had very small sample sizes ranging from 6-12 patients and with the exception of Volovka et al., evaluated the patients after only one hour post injection, a timeframe that was later recognized as generally too short to see an effect in most patients with schizophrenia [39] .
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The second group of naloxone studies administered dosages of 4-10mg and also used BPRS as the endpoint. In this group, there are five studies that, in contrast to those that used lower dosages, were generally much more rigorously designed as reflected by longer duration and larger sample sizes. Four of the five studies [15, 37, 40, 41] , found statistically significant improvement from IV naloxone. The one study that did not find improvement used subcutaneous rather than IV injection for most of the dosages [42] . Subcutaneous and intramuscular administration of naloxone are considered to have similar pharmacokinetics with only 36% bioavailability compared to IV (Table 4) [43].
The third group of naloxone studies consists of seven studies that used dosages above 10mg ranging from 20mg to 2mg/kg. Similar to studies in group 2, IV administration of naloxone tended to demonstrate significant improvement on BPRS [44-46], while subcutaneous or intramuscular administration showed mixed results [47] [48] [49] [50] .
In one of the largest double blind placebo controlled crossover studies of naloxone in schizophrenia, Pickar et al.,1982 recruited 32 (19 medicated and 13 unmedicated) patients with schizophrenia and 26 manic patients from 6 international trial sites [51] . Each patient received a single dose of either subcutaneous 0.3mg/kg naloxone or saline followed by a washout. When combining both the medicated and unmedicated schizophrenic groups, they found a significant improvement in only the BPRS hallucinatory behavior subscale. In the medication treated patients, they also found a significant improvement in total BPRS as well as in the paranoidsuspicion and anxiety-depression subscales. The medicated group also showed a significant improvement in the self-rated Auditory Hallucination Scale. In contrast to the patients with schizophrenia, the manic patients did not show any improvement in symptoms leading the authors to conclude that while naloxone had efficacy in schizophrenia, it was without efficacy in mania.
In the final study of naloxone in patients with schizophrenia, Pickar and colleagues conducted a World Health Organization phase 2 double blind placebo controlled crossover study in 43 patients with schizophrenia [52]. They did not replicate their previous results due to a large placebo response.
IIb. The naltrexone trials
In contrast to the naloxone trials, where patients were usually evaluated within hours after a single dose, the naltrexone trials administered daily dosages for weeks to months and could test efficacy on the negative symptoms. In addition, there were a number of trials testing the ability of naltrexone to help sustain abstinence in dual diagnosed patients with schizophrenia and cooccurring alcohol abuse disorder, and so we will not consider them here. We will consider the naltrexone trials grouped into two daily dose ranges: 1) 100mg, and 2) greater than 100mg. The results of these studies show that 100mg of naltrexone was a generally successful oral dose for treating the positive and negative symptoms of schizophrenia. PET imaging has shown that this dose produces an average of 87% KOR occupancy ( Table 4) [53].
There were three studies with 100mg as the daily dosage. Two of these were conducted by Marchesi et al., and administered 100mg daily naltrexone for two weeks with improvement in the Clinicians Global Improvement scale (CGI) and BPRS over placebo as the endpoints. In the first study Marchesi et al., 1992, in 12 patients, the drug group showed a statistically significant improvement in total BPRS and negative schizophrenia symptoms vs baseline while the placebo group did not show a statistical improvement [54] . In the second study in Marchesi et Finally, in the largest and most rigorous study of opioid antagonists in patients with schizophrenia to date, Tatari et al., 2014 randomized 60 patients who were all stabilized on risperidone to 100mg daily naltrexone or placebo for 12 weeks [56]. They found significant improvement of both positive and negative symptoms vs placebo assessed by the Scales for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS).
There were five studies of naltrexone with dosages greater than 100mg with BPRS as the endpoint. These suffered from either very small sample sizes, or very short durations, and most were either without placebo control or blinding, or both [57] [58] [59] [60] . Sernyak et al., 1998 planned to test 200mg daily naltrexone in 21 patients with schizophrenia stabilized on typical antipsychotics [61] . This was initially designed as a double blind placebo controlled crossover trial, but half way into the trial the blind was broken and many of the patients were not crossed over to the comparator arm.
IIc. Trials with other opioid antagonists
In addition to the previously discussed naloxone and naltrexone trials, there was one successful trial with nalmefene and two with buprenorphine.
In a double blind placebo controlled trial, Schmauss et al., 1987, administered 0.2mg of sublingual buprenorphine, a mu opioid receptor partial agonist and KOR antagonist, to 10 medication free patients with schizophrenia with active positive symptoms [62] . Buprenorphine exhibited an acute antipsychotic effect on the Inpatient Multidimensional Psychiatric Scale (IMPS) in seven of the patients but was ineffective in three patients previously diagnosed with residual schizophrenia. In an open study, Groves and Nutt administered a single dose of 0.2mg of sublingual buprenorphine to seven patients with schizophrenia on antipsychotic medications [63] . They found an acute reduction in BPRS scores particularly, auditory hallucinations, and mood scales.
In 1993, Rapaport et al., tested nalmefene in a double blind placebo controlled crossover trial in 10 patients with schizophrenia on antipsychotics for an average of 36.7 days [64] . They found a significant improvement over baseline in the BPRS thinking disturbance subscale, nurse-rated Bunney-Hamburg psychosis scale, and a trend towards significance in the physician rated Bunney-Hamburg psychosis scale.
Conclusions
In summary, pan-opioid antagonists may have a therapeutic effect on both the positive and negative symptoms of schizophrenia. When viewed in light of the psychotomimetic effects of selective kappa agonists, these trials support the hypothesis that the therapeutic effect of panopioid antagonists may be mediated through the KOR.
III. KORs modulate the dopamine pathways disrupted in schizophrenia
While the role of dopamine in schizophrenia was first hypothesized in the 1960s, the theory that endogenous opioid peptides and their receptors may play a role in the symptoms of schizophrenia was developed more than ten years later in the 1970s. Upon the realization that M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
the endogenous opioid system plays a major role in dopamine regulation, researchers hypothesized a potential link between the two theories. They postulated that the dopamine imbalance in schizophrenia may be a downstream consequence of a disrupted opioid system [65, 66] .
Imaging studies in patients with schizophrenia utilizing PET and Single Photon Emission Computed Tomography (SPECT) have shown an excess of presynaptic striatal dopamine and a deficiency of cortical dopamine [67, 68] . The cortical dopamine deficiency observed in the mesocortical pathway has been hypothesized to play a role in the negative and cognitive symptoms of schizophrenia [69, 70] . The increased presynaptic release of dopamine observed in the striatum of patients with schizophrenia has long been thought to play a critical role in the positive symptoms of schizophrenia. While both the ventral and dorsal striatum have shown increased dopamine release, the magnitude of the increase is much greater in the nigrostriatal pathway to the dorsal striatum, particularly the rostral caudate [67] .
A possible role for KORs in the positive symptoms of schizophrenia
KORs are present on presynaptic axons of the mesolimbic and nigrostriatal dopamine pathways throughout the striatum ( Figure 1A ) [6, [71] [72] [73] [74] where they negatively regulate dopamine release [75] and represent an important mechanism for maintaining dopamine homeostasis and synaptic plasticity [76, 77] . Consistent with this mechanism, rodent studies in vivo have shown that systemic administration of an acute dose of selective KOR agonists reduces dopamine levels in mesolimbic and nigrostriatal pathways via acting on presynaptic KORs on dopaminergic neurons. This was shown with the following selective agonists, U50,488 in the ventral striatum [75, [78] [79] [80] [81] and dorsal striatum [75, 78] , U69,593 in the ventral striatum [82, 83] , spiradoline, and enadoline in the dorsal striatum [84] , and Salvinorin A in the ventral striatum [85] and dorsal striatum [86, 87] (Figure 1B) .
It may seem counterintuitive that increased KOR signaling could play a role in the increased striatal dopamine seen in schizophrenia, as the direct mechanism of KORs is to lower striatal dopamine levels. However, chronic KOR stimulation has been shown to play a role in increasing the amount of presynaptic dopamine released in both the mesolimbic and nigrostriatal paths in response to stimulus or systemic administration of dopaminergic drugs. Chronic administration of U69,593 increases stimulus and drug evoked dopamine levels in both the mesolimbic [88] [89] [90] [91] and nigrostriatal paths ( Figure 1C ) [91] . Similarly, chronic administration of Salvinorin A leads to increased drug evoked dopamine levels in the nigrostriatal pathway [87] . Immediately following chronic administration, basal dopamine levels are unaltered and the ability of an acute systemic dose of U69,593 to reduce dopamine levels is preserved, indicating that stimulated increases in dopamine may not be due to KOR desensitization [73, 88] .
In both the dorsal and ventral striatum, KORs form a complex with the DAT transporter [92] and with both presynaptic D2 autoreceptors on dopamine terminals of the nigrostriatal and mesolimbic paths and postsynaptic D2 receptors on medium spiny neurons (MSNs) [73] . The increase in stimulus and drug evoked dopamine release from both the mesolimbic and nigrostriatal paths following chronic exposure to KOR agonists has been attributed to reduced presynaptic D2 autoreceptor function [88] .
Interestingly, KORs have also been shown to interact with post synaptic D2 receptors on MSNs in ways that may have relevance for schizophrenia. When rodents are exposed to chronic doses of the D2/D3 agonist quinpirole, or drugs that increase dopamine levels such as amphetamine, M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT they exhibit locomotor sensitization [93] , a phenomenon that involves the sensitization of post synaptic D2 receptors on MSNs [73, 94, 95] . Since it was shown that the activity of antipsychotics correlates with their ability to block the dopamine type 2 (D2) receptor [96, 97] , increased dopamine signaling through post synaptic striatal D2 receptors that have become sensitized has been hypothesized to play a critical role in the positive symptoms of schizophrenia [98] [99] [100] [101] [102] . Importantly, while endogenous levels of KOR signaling do not have an effect on locomotor sensitization [73] , administration of KOR agonists resulting in supraphysiological levels of KOR signaling during the sensitization period both accelerate and potentiate this process [73, 94, 95, 103, 104] .
Both the acceleration and potentiation of sensitization are relevant to schizophrenia for two reasons. First, the acceleration of locomotor sensitization has been attributed to the ability of presynaptic KORs to directly increase presynaptic D2 autoreceptor function on dopaminergic terminals where they colocalize, resulting in faster inhibitory responses in presynaptic D2 receptors as measured by fast scan cyclic voltammetry [73] . This reduces phasic dopamine release resulting in accelerated sensitization of post synaptic D2 receptors on MSNs ( Figure  1D-F) [73] . Second, the potentiation of locomotor sensitization has been attributed to be due to both presynaptic KORs colocalized with D2 autoreceptors and post synaptic KORs colocalized with D2 receptors on MSNs. In both of these locations, KORs are hypothesized to increase the efficacy of the D2 receptor signaling [73, 94] , possibly through stabilizing the pre and post synaptic D2 receptor or increasing second messenger coupling [73] .
Finally, it has been proposed that the timing of KOR activation and neural context of elevated dopamine levels plays a critical role in the outcome of chronic KOR activation on sensitization [94] , as it has been shown that KOR activation has the opposite effect on sensitization if administered sequentially with dopamine agonists rather than simultaneously [105] [106] [107] [108] . The importance of neural context is further supported by acute studies of KOR on dopamine release showing that the effects of U50,488 and Salvinorin A on drug and stimulus evoked dopamine response shift from inhibition to potentiation depending on the time of KOR agonist administration relative to stimulus [109, 110] .
In conclusion, we have shown there are several ways KORs may contribute to the positive symptoms of schizophrenia. First, chronic overactivation of KORs in the context of the dysregulated dopamine system in schizophrenia may contribute to the increased presynaptic striatal dopamine release by interacting with presynaptic D2 autoreceptors to modulate the response of the dopamine system to various stimuli. Second, although KORs have not been shown to result in greater total levels of sensitized post synaptic D2 receptors [73] , the fact that presynaptic KORs accelerate sensitization of post synaptic D2 receptors and post synaptic KORs increase signaling through sensitized post synaptic D2 receptors, has potential relevance to the positive symptoms of schizophrenia. While the mechanisms underlying the therapeutic effects of blocking the D2 receptor, as well as the mechanism of the striatal dopamine excess, seen in schizophrenia is yet unknown, the KOR is uniquely positioned to play a possible role in this pathology.
A possible role for KORs in the negative and cognitive symptoms of schizophrenia.
Presynaptic activation of KORs on mesocortical projection neurons have been shown to decrease dopamine in the medial prefrontal cortex (mPFC) of the rodent, an effect that can be blocked by kappa antagonist nor-BNI both in vitro [111] and in vivo [112] . It has also been M A N U S C R I P T
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shown that KOR activation in the mPFC produces conditioned place aversion [113] . Additionally, KOR activation on the soma of mesocortical dopamine projection neurons in in the ventral tegmental area (VTA) inhibits dopamine release in the mPFC [114] . By decreasing mesocortical dopamine release, a hypothetical over-activation of KORs could play a role in the cortical dopamine deficit observed in patients with schizophrenia. Although, the relationship is likely more complex, as chronic treatment with U69,593 increases potassium stimulated dopamine levels (Figure 1G-1F) [115] .
Excessive kappa opioid activation could also play a possible role in the cognitive symptoms. Behavioral studies in rodents show that kappa opioid agonists can cause cognitive deficits. The selective kappa agonist U-50488H induces a dose dependent reduction of prepulse inhibition (PPI), which can be restored by the KOR antagonist norBNI and atypical antipsychotic clozapine but not by the typical antipsychotic haloperidol [116] . In contrast, another study using U50,488, U69,593, and Salvinorin A, did not find any effect on PPI [117] . The kappa agonists U689593, U50488, and GR89,696 all produce impairment of attention as measured by the 5-choice serial reaction time task (5CSRTT), and this disruption can be reversed by naltrexone [118] . Salvinorin A also causes impairment on the 5CSRTT, an effect that can be blocked by pretreatment with the selective kappa antagonist JDTic [119] . Additionally, Salvinorin A has been shown to cause cognitive dysfunction and disruption of learning and memory [120] . Most recently, it was shown that U-50488H induced cognitive disruption as measured by the differential reinforcement of low response rate task (DRL) and cognitive deficits could be blocked by the selective kappa antagonist nor-BNI [121] . Additionally, selective KOR agonist enadoline (CI-977) [122] was shown to induce cognitive impairment in rhesus monkeys on the continuous performance task [123] . It is important to note that this may depend on the state of the system as enadoline and U50488 have both been shown to have acute neuroprotective effects in animals if administered immediately prior to the onset of ischemic brain damage [124] [125] [126] [127] [128] .
Ultimately, the complete mechanism underlying the positive and negative symptoms of schizophrenia may likely involve contributions from other brain regions and neurotransmitter systems. KORs also modulate glutamate neurotransmission in the VTA [129] and are present throughout diverse brain regions that have been implicated in the pathology of schizophrenia including the hippocampus, locus coeruleus, hypothalamus, and amygdala. For a comprehensive review of KORs in other brain regions please see [130] [131] [132] .
Histological studies in patients with schizophrenia have shown abnormalities in the DYN/KOR system.
The evidence for elevated dynorphin or other endorphins is mixed. Heikkilä et al., 1990 found that elevated levels of dynorphin in the CSF of patients with schizophrenia compared to healthy controls correlated with worsening BPRS scores [133] . In another, larger study of 120 hospitalized patients with schizophrenia, Lindtrom et al., found that elevated dynorphin levels were predicative of worse disease outcomes [134] . Another study of 35 patients with schizophrenia found lower levels of dynorphin in the CSF, however, this was when compared with patients with various neurologic diseases including tumors rather than healthy controls [135] . In addition to dynorphin, there have been other studies showing increased beta-endorphin [136] [137] [138] . In contrast, another study did not replicate these findings [139] .
In a limited sample of four patients and four controls, Royston and colleagues found that the KOR distribution in the parahippocampal gyrus was significantly different from normal [140] , M A N U S C R I P T
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10 although the significance of this is unclear. In a post mortem study of both patients with schizophrenia and bipolar disorder, Peckys and Hurd did not find any significant difference in the expression of prodynorphin and KOR mRNA, in the frontal cortex [141] .
Concluding remarks
In conclusion, while there are several generations of antipsychotic drugs effective for treating the positive symptoms of schizophrenia, not all patients fully respond to the antipsychotics with safer clinical profiles. Clozapine, the most effective antipsychotic and drug of last resort for many non-responders, is often not prescribed due to fear of side effects. Additionally, there are currently no effective treatments for the negative or cognitive symptoms [142] . There is a need to examine novel targets to find effective treatments for the negative and cognitive symptoms, as well as to find safer and more effective treatments for the positive symptoms for nonresponders. This review shows that the KOR may be a reasonable new therapeutic target to investigate further and we hope that our review will provide support for additional studies targeting this mechanism for the treatment of positive and negative symptoms in schizophrenia. Table 1 . Kappa agonists cause psychotomimesis in healthy volunteers. 
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